Immune-related Adverse Event of Colitis due to Pembrolizumab Treatment

Abstract

The use of immune checkpoint inhibitors (ICIs) for treating malignant tumors, including head and neck cancer, is gradually expanding. However, various side effects of ICI therapy that are considered immunerelated adverse events (irAEs) have been reported. Diarrhea and colitis are among the most commonly reported irAEs. Although en-